SAM-e
S-Adenosyl Methionine
TL;DR
SAM-e is the body's universal methyl donor. It has solid trial evidence for depression and osteoarthritis at 400-1600 mg/day, but real risks in bipolar disorder and with antidepressants.
Ideal For
- Adults with mild to moderate depression not on serotonergic medication
- People with osteoarthritis who cannot tolerate NSAIDs
- Those with SSRI partial response, under psychiatric supervision
- People with cholestatic liver conditions, with medical input
Avoid If
- You have bipolar disorder or a family history of it
- You take an SSRI, SNRI, MAOI, tramadol or triptan without medical supervision
- You have Parkinson's disease and take levodopa
- You have an anxiety disorder that worsens with activation
- You are pregnant or breastfeeding
Frequently Asked Questions
Overview
S-adenosylmethionine is formed from methionine and ATP, and it is the methyl donor for more than a hundred enzymatic reactions — synthesis of neurotransmitters, phospholipid membrane methylation, DNA and histone methylation, and phase II liver conjugation. It sits at the intersection of the folate, B12 and methionine cycles, which is why B-vitamin status largely determines how well the body regenerates it.
Two clinical uses have credible evidence. In depression, meta-analyses find SAM-e comparable to tricyclic antidepressants and superior to placebo, with a faster onset than typical SSRIs, and adjunctive trials show benefit in SSRI non-responders. In osteoarthritis, a Cochrane review found it comparable to NSAIDs for pain and function with markedly fewer gastrointestinal adverse effects, though onset takes several weeks rather than days. It also has European licensed use in intrahepatic cholestasis.
The safety picture demands attention. SAM-e can precipitate mania or hypomania in bipolar disorder, and this is not a theoretical concern. It carries serotonin syndrome risk when combined with SSRIs, SNRIs, MAOIs, tramadol or triptans. Homocysteine can rise if B6, B12 and folate are inadequate, so co-supplementation is standard. Enteric coating is essential, since unprotected SAM-e degrades in stomach acid.
How It Works
- Universal methyl donor for over 100 methyltransferase reactions
- Supports synthesis and turnover of dopamine, serotonin and noradrenaline
- Methylates phospholipids, improving neuronal membrane fluidity and receptor function
- Stimulates proteoglycan synthesis by chondrocytes in cartilage
- Precursor to glutathione via the transsulfuration pathway
- Supports phase II hepatic conjugation and bile flow
Quick Facts
- Supports mood and emotional well-being
- Promotes joint health and mobility
- Supports liver detoxification
- Essential for methylation processes
- Naturally produced but decreases with age
Benefits & Outcomes
Depression Symptom Reduction
SAM-e has solid trial evidence in depression, including as an add-on for partial SSRI responders.
Serotonin Support
SAM-e supports monoamine synthesis and has reasonable depression trial data, but it is expensive and can destabilise bipolar disorder.
Mood Stabilization
SAM-e has genuine antidepressant signal, including as an SSRI adjunct, but trial quality is limited and it can destabilise bipolar mood.
Joint Comfort
SAM-e performs comparably to NSAIDs for osteoarthritis pain in several trials, with slower onset and better tolerability.
Cognitive Function
Cognitive benefits of SAM-e are largely inferred from its mood effects rather than directly demonstrated.
Cellular Health
SAM-e is the body main methyl donor, but supplementing it has not been shown to improve general cellular health markers.
Health Concerns Addressed
No linked health concerns yet.
Supporting Research7 studies
S-adenosyl methionine (SAMe) for depression in adults
Galizia I, Oldani L, Macritchie K +7 more
SAMe was not clearly superior to placebo for depressive symptoms, and evidence versus standard antidepressants was of low quality.
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
Papakostas GI, et al
These preliminary results suggest that SAMe can be an effective, well-tolerated, and safe adjunctive treatment strategy for SRI nonresponders with major depressive disorder and warrant replication.
Dietary supplements for preventing postnatal depression
Miller BJ, Murray L, Beckmann MM +1 more
To assess the benefits of dietary supplements for preventing postnatal depression either in the antenatal period, postnatal period, or both.
S-Adenosylmethionine for osteoarthritis of the knee or hip
Rutjes AWS, Nuesch E, Reichenbach S
S-Adenosylmethionine may be a viable treatment option but the evidence about its effectiveness and safety is equivocal.
S-Adenosyl methionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial
Sarris J, Murphy J, Stough C +12 more
SAMe monotherapy did not significantly outperform placebo on depression rating scales over eight weeks.
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
Papakostas GI, Mischoulon D, Shyu I +2 more
SAMe 800 mg twice daily added to SSRIs raised response rates to 36 percent versus 18 percent with placebo augmentation.
S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research
Sharma A, Gerbarg P, Bottiglieri T
SAMe shows antidepressant signal mainly as adjunctive therapy, with a favourable safety profile aside from possible activation or mania risk in bipolar disorder.
Safety Information
Potential Side Effects
Nausea, dry mouth, restlessness, insomnia if taken late, headache and mild gastrointestinal upset, usually early and dose-related. The serious risks are mania in bipolar disorder and serotonin syndrome in combination with serotonergic drugs.
Contraindications
Contraindicated in bipolar disorder, where it can trigger mania or hypomania. Do not combine with MAOIs. Use only with medical supervision alongside any serotonergic drug. Caution in Parkinson's disease, where it may reduce levodopa efficacy through methylation.
Drug Interactions
- SSRIs, SNRIs and MAOIs — serotonin syndrome risk
- Tramadol, triptans, meperidine and dextromethorphan — additive serotonergic effect
- Levodopa — SAM-e methylates levodopa and may reduce efficacy
- St John's Wort and 5-HTP — additive serotonergic risk
- Warfarin — limited reports of altered INR
Pregnancy & Breastfeeding
Pregnancy: insufficient_data
Breastfeeding: insufficient_data
Dosage Guidelines
Dosage Used in Studies
400-1600 mg
Best Time to Take
Morning and early afternoon — evening dosing frequently causes insomnia
Best Form
Enteric-coated SAM-e tosylate disulfate, stored cool and dry, taken with B6, B12 and folate
Bioavailability
Unstable molecule - enteric coating protects from stomach acid. Methyl donor involved in numerous biochemical reactions. Effects on mood may take 2-4 weeks. Can be activating - avoid evening doses.
Forms Compared
Enteric-coated SAM-e tosylate disulfate
SAM-e butanedisulfonate
Non-enteric SAM-e
Food & Timing
On an empty stomach, 30 minutes before food, for best absorption
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.